Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.

ABSTRACT:

Purpose

Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; however, tools to quantify in situ drug exposure are few. We have investigated the potential of programmed death-ligand 1 (PD-L1) pharmacodynamics, quantified using PET, to inform on the tumor exposure of anti-PD-L1 (aPD-L1) therapeutics.

Experimental design

To noninvasively quantify PD-L1 levels, we first developed a novel peptide-based gallium-68-labeled binder, [68Ga]Ga-DK223, and evaluated its in vivo distribution, pharmacokinetics, and PD-L1 specificity in preclinical models of triple-negative breast cancer and urothelial carcinoma with var

SUBMITTER: Mishra A 

PROVIDER: S-EPMC9890130 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature